Literature DB >> 23798677

Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation.

Naniye Cetinbas1, Helen Huang-Hobbs, Cristina Tognon, Gabriel Leprivier, Jianghong An, Steven McKinney, Mary Bowden, Connie Chow, Martin Gleave, Lawrence P McIntosh, Poul H Sorensen.   

Abstract

The ETV6-NTRK3 (EN) chimeric oncogene is expressed in diverse tumor types. EN is generated by a t(12;15) translocation, which fuses the N-terminal SAM (sterile α-motif) domain of the ETV6 (or TEL) transcription factor to the C-terminal PTK (protein-tyrosine kinase) domain of the neurotrophin-3 receptor NTRK3. SAM domain-mediated polymerization of EN leads to constitutive activation of the PTK domain and constitutive signaling of the Ras-MAPK and PI3K-Akt pathways, which are essential for EN oncogenesis. Here we show through complementary biophysical and cellular biological techniques that mutation of Lys-99, which participates in a salt bridge at the SAM polymer interface, reduces self-association of the isolated SAM domain as well as high molecular mass complex formation of EN and abrogates the transformation activity of EN. We also show that mutation of Asp-101, the intermolecular salt bridge partner of Lys-99, similarly blocks transformation of NIH3T3 cells by EN, reduces EN tyrosine phosphorylation, inhibits Akt and Mek1/2 signaling downstream of EN, and abolishes tumor formation in nude mice. In contrast, mutations of Glu-100 and Arg-103, residues in the vicinity of the interdomain Lys-99-Asp-101 salt bridge, have little or no effect on these oncogenic characteristics of EN. Our results underscore the importance of specific electrostatic interactions for SAM polymerization and EN transformation.

Entities:  

Keywords:  Cancer Biology; Cell Signaling; ETV6-NTRK3; Ets Family Transcription Factor; Fusion Oncogene; Fusion Protein; Oncogene; SAM Domain

Mesh:

Substances:

Year:  2013        PMID: 23798677      PMCID: PMC3784708          DOI: 10.1074/jbc.M113.475301

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.

Authors:  C A Kim; M L Phillips; W Kim; M Gingery; H H Tran; M A Robinson; S Faham; J U Bowie
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.

Authors:  D H Wai; S R Knezevich; T Lucas; B Jansen; R J Kay; P H Sorensen
Journal:  Oncogene       Date:  2000-02-17       Impact factor: 9.867

Review 3.  ETV6 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Audrey Basinko; Marc De Braekeleer
Journal:  Leuk Res       Date:  2012-05-12       Impact factor: 3.156

4.  The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.

Authors:  C Tognon; M Garnett; E Kenward; R Kay; K Morrison; P H Sorensen
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

5.  Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).

Authors:  Y Kuno; A Abe; N Emi; M Iida; T Yokozawa; M Towatari; M Tanimoto; H Saito
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

6.  Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor.

Authors:  Lauren D Wood; Brenda J Irvin; Giuseppina Nucifora; K Scott Luce; Scott W Hiebert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

7.  Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

Authors:  F Yagasaki; D Wakao; Y Yokoyama; Y Uchida; I Murohashi; H Kayano; M Taniwaki; A Matsuda; M Bessho
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

8.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

Authors:  Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

9.  ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.

Authors:  Kevin B Morrison; Cristina E Tognon; Mathew J Garnett; Cheri Deal; Poul H B Sorensen
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867

10.  Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor.

Authors:  Seong-Woon Yu; Hongmin Wang; Marc F Poitras; Carmen Coombs; William J Bowers; Howard J Federoff; Guy G Poirier; Ted M Dawson; Valina L Dawson
Journal:  Science       Date:  2002-07-12       Impact factor: 47.728

View more
  8 in total

Review 1.  Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.

Authors:  Fredrik Mertens; Cristina R Antonescu; Felix Mitelman
Journal:  Genes Chromosomes Cancer       Date:  2015-12-18       Impact factor: 5.006

2.  Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

Authors:  Gregor Krings; Nancy M Joseph; Gregory R Bean; David Solomon; Courtney Onodera; Eric Talevich; Iwei Yeh; James P Grenert; Elizabeth Hosfield; Emily D Crawford; Richard C Jordan; Annemieke van Zante; Charles Zaloudek; Sandra J Shin; Yunn-Yi Chen
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

3.  Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Authors:  Jinah Park; Junil Kim; Bora Park; Kyung-Min Yang; Eun Jin Sun; Cristina E Tognon; Poul H Sorensen; Seong-Jin Kim
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

4.  Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.

Authors:  Cristina E Tognon; Bo Rafn; Naniye Malli Cetinbas; Takumi Kamura; Genny Trigo; Barak Rotblat; Fumihiko Okumura; Masaki Matsumoto; Christine Chow; Monika Davare; Michael Pollak; Thibault Mayor; Poul H Sorensen
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

5.  Oncogenic rearrangements driving ionizing radiation-associated human cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

6.  Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression.

Authors:  C Matthew Hope; Jemma L Webber; Sherzod A Tokamov; Ilaria Rebay
Journal:  Elife       Date:  2018-11-09       Impact factor: 8.140

7.  Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation.

Authors:  Malalage N Peiris; April N Meyer; Katelyn N Nelson; Ezra W Bisom-Rapp; Daniel J Donoghue
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

8.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.

Authors:  Gang Wu; Alexander K Diaz; Barbara S Paugh; Sherri L Rankin; Bensheng Ju; Yongjin Li; Xiaoyan Zhu; Chunxu Qu; Xiang Chen; Junyuan Zhang; John Easton; Michael Edmonson; Xiaotu Ma; Charles Lu; Panduka Nagahawatte; Erin Hedlund; Michael Rusch; Stanley Pounds; Tong Lin; Arzu Onar-Thomas; Robert Huether; Richard Kriwacki; Matthew Parker; Pankaj Gupta; Jared Becksfort; Lei Wei; Heather L Mulder; Kristy Boggs; Bhavin Vadodaria; Donald Yergeau; Jake C Russell; Kerri Ochoa; Robert S Fulton; Lucinda L Fulton; Chris Jones; Frederick A Boop; Alberto Broniscer; Cynthia Wetmore; Amar Gajjar; Li Ding; Elaine R Mardis; Richard K Wilson; Michael R Taylor; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.